{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T03:46:25Z","timestamp":1783741585635,"version":"3.55.0"},"reference-count":58,"publisher":"Bentham Science Publishers Ltd.","issue":"2","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["PRA"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>SV-BR-1-GM, derived from a patient with grade 2 (moderately differentiated) breast cancer, is a GM-CSF-secreting breast cancer cell line with properties of antigen-presenting cells. SV-BR-1-GM and next-generation versions are covered by several pending and granted patents.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>We report findings from an open-label phase I, single-arm pilot study with irradiated SV-BR-1-GM cells in 3 breast and 1 ovarian cancer subjects. Inoculations were preceded by low-dose intravenous cyclophosphamide and followed by interferon-alpha2b injections into the SV-BR-1-GM inoculation sites. We assessed both cellular and humoral immune responses, and measured expression levels of SV-BR-1-GM HLA alleles.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Treatment was generally safe and well tolerated. Immune responses were elicited universally. Overall survival was more than 33 months for three of the four patients. As previously reported, one patient had prompt regression of metastases in lung, breast, and soft tissue. Following cessation of treatment, the patient relapsed widely, including in the brain. Upon retreatment, rapid tumor response was again seen, including complete regression of brain metastases. Consistent with a role of Class II HLA in contributing to SV-BR-1-GM\u2019s mechanism of action, this patient allele-matched SV-BR-1-GM at the HLA-DRB1 and HLA-DRB3 loci. We are in the process of developing next-generation SV-BR-1-GM, expressing patient-specific HLAs. Patent applications were filed in various jurisdictions. Thus far, one is granted, in Japan.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>A whole-cell immunotherapy regimen with SV-BR-1-GM cells induced regression of met-astatic breast cancer. We develop intellectual property based on SV-BR-1-GM\u2019s predicted mechanism of action to develop additional whole-cell immunotherapies for cancer patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Clinical Trail Registration:<\/jats:title>\n<jats:p>This clinical trial was registered under ClinicalTrials.gov Identifier NCT00095862.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574892817666220518123331","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T10:42:15Z","timestamp":1653043335000},"page":"224-240","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Regression of Breast Cancer Metastases Following Treatment with\nIrradiated SV-BR-1-GM, a GM-CSF Overexpressing Breast Cancer Cell\nLine: Intellectual Property and Immune Markers of Response"],"prefix":"10.2174","volume":"18","author":[{"given":"Charles L.","family":"Wiseman","sequence":"first","affiliation":[{"name":"BriaCell Therapeutics Corporation, 2929 Arch Street, 3rd Floor, Philadelphia, PA, 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kharazi","sequence":"additional","affiliation":[{"name":"Immunotherapy Laboratory, St. Vincent Medical Center, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivekananda G.","family":"Sunkari","sequence":"additional","affiliation":[{"name":"BriaCell Therapeutics Corporation, 2929 Arch Street, 3rd Floor, Philadelphia, PA, 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline L.","family":"Galeas","sequence":"additional","affiliation":[{"name":"BriaCell Therapeutics Corporation, 2929 Arch Street, 3rd Floor, Philadelphia, PA, 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Dozio","sequence":"additional","affiliation":[{"name":"Operations\nDepartment, Biognosys AG, Wagistrasse 21, 8952, Schlieren, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hind","family":"Hashwah","sequence":"additional","affiliation":[{"name":"Sales and Marketing Nebion AG, Hohlstrasse\n515, 8048, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Mac\u00fachov\u00e1","sequence":"additional","affiliation":[{"name":"Sales and Marketing Nebion AG, Hohlstrasse\n515, 8048, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William V.","family":"Williams","sequence":"additional","affiliation":[{"name":"BriaCell Therapeutics Corporation, 2929 Arch Street, 3rd Floor, Philadelphia, PA, 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus D.","family":"Lacher","sequence":"additional","affiliation":[{"name":"BriaCell Therapeutics Corporation, 2929 Arch Street, 3rd Floor, Philadelphia, PA, 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40425-014-0031-3","volume":"2","author":"Santegoets S.J.","year":"2014","unstructured":"Santegoets S.J.; Stam A.G.; Lougheed S.M.; Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. J Immunother Cancer 2014,2(1),31","journal-title":"J Immunother Cancer"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1158\/2326-6066.CIR-14-0058","volume":"2","author":"Chen G.","year":"2014","unstructured":"Chen G.; Gupta R.; Petrik S.; A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. Cancer Immunol Res 2014,2(10),949-961","journal-title":"Cancer Immunol Res"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/CJI.0b013e3182a80237","volume":"36","author":"Creelan B.C.","year":"2013","unstructured":"Creelan B.C.; Antonia S.; Noyes D.; Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma. J Immunother 2013,36(8),442-450","journal-title":"J Immunother"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1200\/JCO.2014.57.4244","volume":"33","author":"Le D.T.","year":"2015","unstructured":"Le D.T.; Wang-Gillam A.; Picozzi V.; Safety and survival with GVAX pancreas prime and Listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol 2015,33(12),1325-1333","journal-title":"J Clin Oncol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12967-015-0572-3","volume":"13","author":"Lipson E.J.","year":"2015","unstructured":"Lipson E.J.; Sharfman W.H.; Chen S.; Safety and immunologic correlates of melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting. J Transl Med 2015,13(1),214","journal-title":"J Transl Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s10434-001-0198-y","volume":"8","author":"Tsioulias G.J.","year":"2001","unstructured":"Tsioulias G.J.; Gupta R.K.; Tisman G.; Serum TA90 antigen-antibody complex as a surrogate marker for the efficacy of a polyvalent allogeneic whole-cell vaccine (CancerVax) in melanoma. Ann Surg Oncol 2001,8(3),198-203","journal-title":"Ann Surg Oncol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nm1100","volume":"10","author":"Rosenberg S.A.","year":"2004","unstructured":"Rosenberg S.A.; Yang J.C.; Restifo N.P.; Cancer immunotherapy: Moving beyond current vaccines. Nat Med 2004,10(9),909-915","journal-title":"Nat Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","volume":"17","author":"Cheever M.A.","year":"2011","unstructured":"Cheever M.A.; Higano C.S.; PROVENGE (Sipuleucel-T) in prostate cancer: The first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 2011,17(11),3520-3526","journal-title":"Clin Cancer Res"},{"key":"ref=9","first-page":"3222","volume":"9","author":"Ko B.K.","year":"2003","unstructured":"Ko B.K.; Kawano K.; Murray J.L.; Clinical studies of vaccines targeting breast cancer. Clin Cancer Res 2003,9(9),3222-3234","journal-title":"Clin Cancer Res"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"101947","DOI":"10.1016\/j.ctrv.2019.101947","volume":"84","author":"Solinas C.","year":"2020","unstructured":"Solinas C.; Aiello M.; Migliori E.; Willard-Gallo K.; Emens L.A.; Breast cancer vaccines: Heeding the lessons of the past to guide a path forward. Cancer Treat Rev 2020,84,101947","journal-title":"Cancer Treat Rev"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/sj.cgt.7700950","volume":"13","author":"Sobol R.E.","year":"2006","unstructured":"Sobol R.E.; The rationale for prophylactic cancer vaccines and need for a paradigm shift. Cancer Gene Ther 2006,13(8),725-731","journal-title":"Cancer Gene Ther"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1600-065X.1997.tb00982.x","volume":"157","author":"Cheever M.A.","year":"1997","unstructured":"Cheever M.A.; Chen W.; Therapy with cultured T cells: Principles revisited. Immunol Rev 1997,157(1),177-194","journal-title":"Immunol Rev"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/j.1098-2388.1993.tb00019.x","volume":"9","author":"Elliott G.T.","year":"1993","unstructured":"Elliott G.T.; McLeod R.A.; Perez J.; Von Eschen K.B.; Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma. Semin Surg Oncol 1993,9(3),264-272","journal-title":"Semin Surg Oncol"},{"key":"ref=14","first-page":"421","volume":"57","author":"Mordoh J.","year":"1997","unstructured":"Mordoh J.; Kairiyama C.; Bover L.; Solarolo E.; Allogeneic cells vaccine increases disease-free survival in stage III melanoma patients. A non randomized phase II study. Medicina (B Aires) 1997,57(4),421-427","journal-title":"Medicina (B Aires)"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/sj.cgt.7700922","volume":"13","author":"Nemunaitis J.","year":"2006","unstructured":"Nemunaitis J.; Jahan T.; Ross H.; Phase 1\/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther 2006,13(6),555-562","journal-title":"Cancer Gene Ther"},{"key":"ref=16","first-page":"3696","volume":"8","author":"Vaishampayan U.","year":"2002","unstructured":"Vaishampayan U.; Abrams J.; Darrah D.; Jones V.; Mitchell M.S.; Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha. Clin Cancer Res 2002,8(12),3696-3701","journal-title":"Clin Cancer Res"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1517\/13543784.2012.684753","volume":"21","author":"Mackiewicz A.","year":"2012","unstructured":"Mackiewicz A.; Mackiewicz J.; Wysocki P.J.; Long-term survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection. Expert Opin Investig Drugs 2012,21(6),773-783","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11605-012-2064-6","volume":"17","author":"Hardacre J.M.","year":"2013","unstructured":"Hardacre J.M.; Mulcahy M.; Small W.; Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: A phase 2 study. J Gastrointest Surg 2013,17(1),94-100","journal-title":"J Gastrointest Surg"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"e853","DOI":"10.1097\/MD.0000000000000853","volume":"94","author":"Mackiewicz J.","year":"2015","unstructured":"Mackiewicz J.; Karczewska-Dzionk A.; Laciak M.; Whole cell therapeutic vaccine modified with hyper-IL6 for combinational treatment of nonresected advanced melanoma. Medicine (Baltimore) 2015,94(21),e853","journal-title":"Medicine (Baltimore)"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1016\/j.ejca.2015.07.035","volume":"51","author":"Giaccone G.","year":"2015","unstructured":"Giaccone G.; Bazhenova L.A.; Nemunaitis J.; A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer 2015,51(16),2321-2329","journal-title":"Eur J Cancer"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3389\/fimmu.2018.00776","volume":"9","author":"Lacher M.D.","year":"2018","unstructured":"Lacher M.D.; Bauer G.; Fury B.; SV-BR-1-GM, a clinically effective GM-CSF-secreting breast cancer cell line, expresses an immune signature and directly activates CD4+ T lymphocytes. Front Immunol 2018,9,776","journal-title":"Front Immunol"},{"key":"ref=22","author":"Lacher MD","year":"2017","unstructured":"Lacher MD; Wagner JP; Wiseman CL; Williams WV; Whole-cell cancer vaccines and methods for selection thereof. 2017"},{"key":"ref=23","author":"Eisenbach L","year":"1993","unstructured":"Eisenbach L; Feldman M.; Double transfectants of MHC genes as cellular vaccines for immunoprevention of tumor metastasis. 1993"},{"key":"ref=24","author":"Eisenbach L.","year":"1998","unstructured":"Eisenbach L.; Feldman M.; Double transfectants of the MHC genes as cellular vaccines for immuno prevention of tumor metastasis. 1998"},{"key":"ref=25","author":"Ostrand-Rosenberg S.","year":"2000","unstructured":"Ostrand-Rosenberg S.; Baskar S.; Glimcher L.H.; Freeman G.J.; Nadler L.M.; Tumor cells with increased immunogenicity and uses therefor. 2000"},{"key":"ref=26","author":"Podack E.","year":"2010","unstructured":"Podack E.; Tumor vaccine. 2010"},{"key":"ref=27","author":"Ostrand-Rosenberg S.","year":"2010","unstructured":"Ostrand-Rosenberg S.; Bosch J.J.; Ksander B.R.; Tumor cells from immune privileged sites as base cells for cell-based cancer vaccines. 2010"},{"key":"ref=28","author":"Tamar Peretz T","year":"2012","unstructured":"Tamar Peretz T; Lotem M; Machlenkin A; Allogeneic tumor cell vaccination. 2012"},{"key":"ref=29","author":"Wiseman C.","year":"2010","unstructured":"Wiseman C.; Kharazi A.; Breast cancer cell lines and uses thereof. 2010"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1075-122X.2006.00319.x","volume":"12","author":"Wiseman C.L.","year":"2006","unstructured":"Wiseman C.L.; Kharazi A.; Objective clinical regression of metastatic breast cancer in disparate sites after use of whole-cell vaccine genetically modified to release sargramostim. Breast J 2006,12(5),475-480","journal-title":"Breast J"},{"key":"ref=31","author":"Lacher MD","year":"2019","unstructured":"Lacher MD; Wagner JP; Wiseman CL; Williams WV; Whole-cell cancer vaccines and methods for selection thereof. 2019"},{"key":"ref=32","author":"Lacher MD","year":"2021","unstructured":"Lacher MD; Wagner JP; Wiseman CL; Williams WV; Whole-cell cancer vaccines and methods for selection thereof. 2021"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/1876817201002010004","volume":"2","author":"Wiseman C.L.","year":"2010","unstructured":"Wiseman C.L.; Kharazi A.; Phase I.; Study with SV-BR-1 breast cancer cell line vaccine and GM-CSF: Clinical experience in 14 patients. Open Breast Cancer J 2010,2(1),4-11","journal-title":"Open Breast Cancer J"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1074\/mcp.RA117.000314","volume":"16","author":"Bruderer R.","year":"2017","unstructured":"Bruderer R.; Bernhardt O.M.; Gandhi T.; Optimization of experimental parameters in data-independent mass spectrometry significantly increases depth and reproducibility of results. Mol Cell Proteomics 2017,16(12),2296-2309","journal-title":"Mol Cell Proteomics"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.1074\/mcp.M114.043489","volume":"13","author":"Scheltema R.A.","year":"2014","unstructured":"Scheltema R.A.; Hauschild J.P.; Lange O.; The Q exactive HF, a benchtop mass spectrometer with a pre-filter, high-performance quadrupole and an ultra-high-field orbitrap analyzer. Mol Cell Proteomics 2014,13(12),3698-3708","journal-title":"Mol Cell Proteomics"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/nbt0816-888d","volume":"34","author":"Bray N.L.","year":"2016","unstructured":"Bray N.L.; Pimentel H.; Melsted P.; Pachter L.; Erratum: Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol 2016,34(8),888","journal-title":"Nat Biotechnol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nbt.3519","volume":"34","author":"Bray N.L.","year":"2016","unstructured":"Bray N.L.; Pimentel H.; Melsted P.; Pachter L.; Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol 2016,34(5),525-527","journal-title":"Nat Biotechnol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/nmeth.4324","volume":"14","author":"Pimentel H.","year":"2017","unstructured":"Pimentel H.; Bray N.L.; Puente S.; Melsted P.; Pachter L.; Differential analysis of RNA-seq incorporating quantification uncertainty. Nat Methods 2017,14(7),687-690","journal-title":"Nat Methods"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1038\/nprot.2009.97","volume":"4","author":"Durinck S.","year":"2009","unstructured":"Durinck S.; Spellman P.T.; Birney E.; Huber W.; Mapping identifiers for the integration of genomic datasets with the R\/Bioconductor package biomaRt. Nat Protoc 2009,4(8),1184-1191","journal-title":"Nat Protoc"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/s12859-017-1714-9","volume":"18","author":"Bush S.J.","year":"2017","unstructured":"Bush S.J.; McCulloch M.E.B.; Summers K.M.; Hume D.A.; Clark E.L.; Integration of quantitated expression estimates from polyA-selected and rRNA-depleted RNA-seq libraries. BMC Bioinformatics 2017,18(1),301","journal-title":"BMC Bioinformatics"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"420747","DOI":"10.1155\/2008\/420747","volume":"2008","author":"Hruz T.","year":"2008","unstructured":"Hruz T.; Laule O.; Szabo G.; Genevestigator v3: A reference expression database for the meta-analysis of transcriptomes. Adv Bioinforma 2008,2008,420747","journal-title":"Adv Bioinforma"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s41598-017-18599-x","volume":"8","author":"Wang S.","year":"2018","unstructured":"Wang S.; Yan R.; Wang B.; Prediction of co-expression genes and integrative analysis of gene microarray and proteomics profile of Keshan disease. Sci Rep 2018,8(1),231","journal-title":"Sci Rep"},{"key":"ref=43","first-page":"D948","volume":"48","author":"Robinson J.","year":"2020","unstructured":"Robinson J.; Barker D.J.; Georgiou X.; Cooper M.A.; Flicek P.; Marsh S.G.E.; IPD-IMGT\/HLA database. Nucleic Acids Res 2020,48(D1),D948-D955","journal-title":"Nucleic Acids Res"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1074\/jbc.270.2.971","volume":"270","author":"Arimilli S.","year":"1995","unstructured":"Arimilli S.; Cardoso C.; Mukku P.; Baichwal V.; Nag B.; Refolding and reconstitution of functionally active complexes of human leukocyte antigen DR2 and myelin basic protein peptide from recombinant alpha and beta polypeptide chains. J Biol Chem 1995,270(2),971-977","journal-title":"J Biol Chem"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","volume":"19","author":"Elston C.W.","year":"1991","unstructured":"Elston C.W.; Ellis I.O.; Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991,19(5),403-410","journal-title":"Histopathology"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.7150\/jca.18457","volume":"8","author":"Dai X.","year":"2017","unstructured":"Dai X.; Cheng H.; Bai Z.; Li J.; Breast cancer cell line classification and its relevance with breast tumor subtyping. J Cancer 2017,8(16),3131-3141","journal-title":"J Cancer"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"469251","DOI":"10.1155\/2014\/469251","volume":"2014","author":"Parise C.A.","year":"2014","unstructured":"Parise C.A.; Caggiano V.; Breast cancer survival defined by the ER\/PR\/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. J Cancer Epidemiol 2014,2014,469251","journal-title":"J Cancer Epidemiol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3389\/fonc.2019.01124","volume":"9","author":"Godoy-Ortiz A.","year":"2019","unstructured":"Godoy-Ortiz A.; Sanchez-Mu&#xF1;oz A.; Chica Parrado M.R.; Deciphering HER2 breast cancer disease: Biological and clinical implications. Front Oncol 2019,9,1124","journal-title":"Front Oncol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/1476-4598-13-228","volume":"13","author":"Sabatier R.","year":"2014","unstructured":"Sabatier R.; Finetti P.; Guille A.; Claudin-low breast cancers: Clinical, pathological, molecular and prognostic characterization. Mol Cancer 2014,13(1),228","journal-title":"Mol Cancer"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"e88557","DOI":"10.1371\/journal.pone.0088557","volume":"9","author":"Soliman H.","year":"2014","unstructured":"Soliman H.; Khalil F.; Antonia S.; PD-L1 expression is increased in a subset of basal type breast cancer cells. PLoS One 2014,9(2),e88557","journal-title":"PLoS One"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"e0138213","DOI":"10.1371\/journal.pone.0138213","volume":"10","author":"Yao F.","year":"2015","unstructured":"Yao F.; Zhang C.; Du W.; Liu C.; Xu Y.; Identification of gene-expression signatures and protein markers for breast cancer grading and staging. PLoS One 2015,10(9),e0138213","journal-title":"PLoS One"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1093\/jnci\/djj052","volume":"98","author":"Sotiriou C.","year":"2006","unstructured":"Sotiriou C.; Wirapati P.; Loi S.; Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006,98(4),262-272","journal-title":"J Natl Cancer Inst"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ccr.2006.10.008","volume":"10","author":"Neve R.M.","year":"2006","unstructured":"Neve R.M.; Chin K.; Fridlyand J.; A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006,10(6),515-527","journal-title":"Cancer Cell"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"D19","DOI":"10.1093\/nar\/gkq1019","volume":"39","author":"Leinonen R.","year":"2011","unstructured":"Leinonen R.; Sugawara H.; Shumway M.; International nucleotide sequence database collaboration. The sequence read archive. Nucleic Acids Res 2011,39(Database issue),D19-D21","journal-title":"Nucleic Acids Res"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"D442","DOI":"10.1093\/nar\/gky1106","volume":"47","author":"Perez-Riverol Y.","year":"2019","unstructured":"Perez-Riverol Y.; Csordas A.; Bai J.; The PRIDE database and related tools and resources in 2019: Improving support for quantification data. Nucleic Acids Res 2019,47(D1),D442-D450","journal-title":"Nucleic Acids Res"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1002\/0471250953.bi0312s48","volume":"48","author":"Lopez R.","year":"2014","unstructured":"Lopez R.; Cowley A.; Li W.; McWilliam H.; Using EMBL-EBI services via web interface and programmatically via web services. Curr Protoc Bioinformatics 2014,48,3121-3150","journal-title":"Curr Protoc Bioinformatics"},{"key":"ref=57","first-page":"418","volume":"39","author":"Park M.H.","year":"2006","unstructured":"Park M.H.; Lee H.J.; Bok J.; Korean BAC library construction and characterization of HLA-DRA, HLA-DRB3. J Biochem Mol Biol 2006,39(4),418-425","journal-title":"J Biochem Mol Biol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1034\/j.1399-0039.2000.550606.x","volume":"55","author":"Coquillard G.J.","year":"2000","unstructured":"Coquillard G.J.; Tang T.F.; Steiner N.; DRB3 alleles with variations in the annealing sites of commonly used amplification primers. Tissue Antigens 2000,55(6),558-563","journal-title":"Tissue Antigens"}],"container-title":["Recent Patents on Anti-Cancer Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574892817666220518123331","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/204979\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574892817666220518123331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T15:59:34Z","timestamp":1692892774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/204979\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574892817666220518123331","relation":{},"ISSN":["1574-8928"],"issn-type":[{"value":"1574-8928","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-10-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}